The risk estimate with pioglitazone was comparable to that seen with rosiglitazone at each fracture site, although the results for pioglitazone failed to reach statistical significance given that relatively fewer patients registered in the GPRD receive pioglitazone.
← all excerpts
The risk of fractures associated with thiazolidinediones: a self-controlled case-series study.
1
—
—